Literature DB >> 15920286

Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Samer Sourial1, Anette Wärnmark, Charlotta Nilsson, Ewa Björling, Adnane Achour, Robert A Harris.   

Abstract

The envelope of the human immunodeficiency virus (HIV) is the main target for neutralizing antibodies. We report the cloning, purification, and characterization of two recombinant forms of the envelope glycoprotein gp125 from a primary HIV-2SBL-6669 isolate. Both constructs were truncated at the N- and C-termini, and in the gp125deltav1v2 construct the variable V1 and V2 loops were deleted. The recombinant glycoproteins were stably expressed in Chinese hamster ovarian cells, producing soluble gp125 and gp125deltav1v2 at molecular weights of 74.2 and 56.9 kDa, respectively, and were purified from cell culture supernatants in a single step using Galanthus nivalis lectin chromatography. Circular dichroism analysis indicated a similar secondary structure for gp125 and gp125deltav1v2, and both proteins were recognized by HIV-2 serum antibodies in surface plasmon resonance assays. The high yield and purity of these constructs makes them suitable for structural and functional analyses, as well as vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920286     DOI: 10.1385/MB:30:2:155

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  30 in total

1.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

4.  Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).

Authors:  P D Kwong; R Wyatt; E Desjardins; J Robinson; J S Culp; B D Hellmig; R W Sweet; J Sodroski; W A Hendrickson
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

5.  A form of circulating ICAM-1 in human serum.

Authors:  R Rothlein; E A Mainolfi; M Czajkowski; S D Marlin
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

6.  A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB.

Authors:  J Albert; U Bredberg; F Chiodi; B Böttiger; E M Fenyö; E Norrby; G Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Authors:  Rob J Center; Richard D Leapman; Jacob Lebowitz; Larry O Arthur; Patricia L Earl; Bernard Moss
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.

Authors:  S Modrow; B H Hahn; G M Shaw; R C Gallo; F Wong-Staal; H Wolf
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

View more
  2 in total

1.  Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis.

Authors:  James M Turman; Alana M Cheplowitz; Charu Tiwari; Thushara Thomas; Dhruvi Joshi; Menakshi Bhat; Qian Wu; Erik Pong; Seung Y Chu; David E Szymkowski; Amit Sharma; Stephanie Seveau; John M Robinson; Jesse J Kwiek; Dennis Burton; Murugesan V S Rajaram; Jonghan Kim; Lars Hangartner; Latha P Ganesan
Journal:  J Immunol       Date:  2021-02-10       Impact factor: 5.422

2.  HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.

Authors:  Batul Diwan; Rupali Saxena; Archana Tiwari
Journal:  Springerplus       Date:  2013-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.